Safety and Efficacy of Selinexor in Combination With Pembrolizumab in Recurrent Advanced Melanoma
Study sponsor: Karyopharm Therapeutics Inc · KPTI
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2023-09-22Actual
Enrollment · participants15Actual
Source updated2024-08-23Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.